US 12,458,656 B2
Advantageous anti-HCV combination therapy
Jean-Pierre Sommadossi, Boston, MA (US); Adel Moussa, Burlington, MA (US); Keith M. Pietropaolo, Boxford, MA (US); and Xiao-Jian Zhou, Arlington, MA (US)
Assigned to Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed by Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed on May 21, 2025, as Appl. No. 19/215,054.
Application 19/215,054 is a continuation of application No. 18/540,608, filed on Dec. 14, 2023.
Application 18/540,608 is a continuation of application No. PCT/US2022/034083, filed on Jun. 17, 2022.
Claims priority of provisional application 63/212,047, filed on Jun. 17, 2021.
Prior Publication US 2025/0281520 A1, Sep. 11, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61K 31/5365 (2006.01); A61P 31/16 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 31/5365 (2013.01); A61P 31/16 (2018.01)] 20 Claims
 
1. A method of treating HCV in a human in need thereof, comprising administering an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
in a dosage form in combination with an effective amount of Compound 2, or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
in a dosage form.